Truist Financial Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics (NASDAQ:PVLA) had its target price boosted by equities research analysts at Truist Financial from $80.00 to $105.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 34.87% from the company’s previous close.

A number of other equities analysts have also recently weighed in on PVLA. Canaccord Genuity Group boosted their price target on Palvella Therapeutics from $66.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Raymond James Financial set a $54.00 price objective on Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. HC Wainwright boosted their target price on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Oppenheimer started coverage on shares of Palvella Therapeutics in a research note on Tuesday, September 9th. They set an “outperform” rating and a $85.00 price target on the stock. Finally, Chardan Capital lifted their price target on shares of Palvella Therapeutics from $73.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $99.67.

Palvella Therapeutics Trading Down 3.0%

Shares of PVLA opened at $77.85 on Monday. Palvella Therapeutics has a 12-month low of $11.17 and a 12-month high of $83.00. The stock has a market cap of $861.02 million, a P/E ratio of -20.54 and a beta of -0.05. The company has a 50-day moving average of $67.15 and a two-hundred day moving average of $43.73.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, November 11th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). As a group, analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Archer Investment Corp purchased a new stake in Palvella Therapeutics during the third quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $37,000. JPMorgan Chase & Co. lifted its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth about $85,000. Finally, BNP Paribas Financial Markets acquired a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $104,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.